The data presented highlights the strong predictive value of oxidative stress biomarker (4-HNE) levels with the rate of disease progression and survival in ALS patients from a longitudinal patient registry cohort.
Peter Sackey further elaborated: "Once the 30-day follow-up of all patients is complete, we will enter into an intense phase of final monitoring, data cleaning and transfer to our statistician team for analysis. In parallel, the long-term outcomes at 3 and 6 months will be collected centrally by the Critical Illness, Brain Dysfunction, and Survivorship team at Vanderbilt Medical Center. With this parallel approach, we expect topline results in the autumn of this year and a swift regulatory submission in Q1, 2025".
The data presented highlights the strong predictive value of oxidative stress biomarker (4-HNE) levels with the rate of disease progression and survival in ALS patients from a longitudinal patient registry cohort.
The study compared the accuracy of two cardiac output monitors, the Retia Argos and the Edwards Lifesciences FloTrac across 58 patients undergoing off-pump coronary artery bypass surgery, yielding 572 sets of cardiac output measurements from each device.
Treatment with VivAer, a non-invasive, temperature-controlled, radiofrequency (RF) device, resulted in significant symptom relief, superior to sham control.
The first patient enrolled in global multi-center randomized controlled trial with 564 patients at 15 sites comparing the impact of the Direct to Angio Suite workflow (diagnosis and treatment in the angio suite) to the conventional workflow (diagnosis in the CT or MRI suite followed by treatment in the angio suite) on stroke patient outcomes. WE-TRUST trial to provide most comprehensive assessment to date with the help of an advanced brain scan technology in the angio suite for more effective and efficient stroke patient outcomes.
DEFINE AFib Study will leverage data from Medtronic insertable cardiac monitors and Medtronic Discovery App™ with the goal of informing atrial fibrillation (AF) management strategies
Medtronic presented real-world clinical results that compared glycemic outcomes for 1,736 individuals before and after using the InPen smart1 insulin pen for 90 days with a glucose monitor
Insulet will present new clinical outcomes data for preschool children with type 1 diabetes using the Omnipod 5 Automated Insulin Delivery System (Omnipod 5).
